KA-3006
/ KYinno
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
The bispecific antibody KA-3006 against both EGFR and MET surpasses amivantamab in efficacy
(AACR 2024)
- "Finally, we assessed the developability of this BsAb with different treatments such as high concentration, low pH, repeated freezing and thawing, and high temperature, and KA-3006 showed neither aggregation nor degradation. In conclusion, the BsAb KA-3006, developed with our common light chain antibody discovery platform, is a promising pre-clinical candidate drug for the treatment of various solid cancers with overactivated EGFR and MET signaling, and it holds potential for developing ADCs targeting both EGFR and MET."
Clinical • Oncology • Solid Tumor • EGFR
1 to 1
Of
1
Go to page
1